Becker muscular dystrophy …

Michele Gatheridge MD

Neuromuscular Disorders

Updated 03.30.2024
Released 09.30.1994
Expires For CME 03.30.2027

Becker muscular dystrophy

Author: Michele Gatheridge MD

See Contributor Disclosures

Editor: Nicholas E Johnson MD MSCI FAAN

Becker muscular dystrophy

In This Article

Quick Link

Introduction

Overview

Becker muscular dystrophy is a genetic neuromuscular disorder with considerable clinical heterogeneity caused by mutations in the DMD gene on the X chromosome. It is less severe compared to the allelic Duchenne form. It is an exciting time in the treatment of Duchenne muscular dystrophy and Becker muscular dystrophy, as we see more and more impactful genetic therapies, including gene therapy, in promising clinical trials.

Key points

	• Becker muscular dystrophy is a multisystem progressive genetic disease that primarily causes skeletal and cardiac muscle degeneration.
	• Becker muscular dystrophy is a milder allelic variant of Duchenne muscular dystrophy.
	• The diagnosis is based on clinical findings of proximal weakness, elevated creatine kinase, and confirmation with genetic testing for mutation in the DMD gene.
	• Cardiomyopathy is a significant cause of morbidity and requires regular medical surveillance.

Historical note and terminology

Becker muscular dystrophy is one of the most common muscle diseases and should be suspected in males at any age with proximal muscle weakness or enlarged muscles, and elevated serum creatine kinase. The name of the disorder comes from Emil Becker, a German physician who published the first extensive studies on this disease in the 1950s (05). Another muscle disease, autosomal recessive congenital myotonia, was also named after him (Becker myotonia congenita). The inheritance of Becker muscular dystrophy is X-linked recessive; however, a large proportion of cases are sporadic.

The molecular genetic cause of Becker muscular dystrophy was elucidated in 1986 and 1987 in a series of studies that is considered an early major triumph of molecular genetics (57; 34; 35; 48). During these studies, it became clear that the more clinically severe Duchenne muscular dystrophy is caused by the same gene and protein defect as Becker muscular dystrophy (allelic disorders).

Clinical manifestations

Presentation and course

	• Becker muscular dystrophy is an X-linked recessive disease characterized by a variable progressive myopathy due to in-frame deletions in the DMD gene.
	• Patients with Becker muscular dystrophy produce some functional dystrophin, unlike the complete absence of dystrophin seen in Duchenne muscular dystrophy. This results in significant variability in clinical presentation and course.
	• Decline in muscle strength is variable; however, all boys with Becker muscular dystrophy show a gradual decline in lower extremity muscle function with age. Loss of ambulation is also highly variable and occurs later than Duchenne muscular dystrophy, typically after 16 years of age, with a mean age in the third decade.
	• Cardiac function should be monitored for occult cardiomyopathy in all patients with Becker muscular dystrophy.

The most common presentations of Becker muscular dystrophy include (1) proximal muscle weakness/myalgias (60%); (2) elevated serum levels of creatine kinase (CK) (32.4%); (3) CNS complications including mental retardation, learning disability, and epilepsy (5.3%); and (4) cardiac complications (1.7%) (60). Malignant hyperthermia after exposure to halothane anesthesia is also a possible presentation, though very rare.

(1) Proximal muscle weakness or myalgias. The most typical presentation of patients with Becker muscular dystrophy is juvenile onset of proximal muscle weakness and calf hypertrophy, with gradual progression. Early myalgia and cramps can also occur in patients with later onset of muscle weakness (29; 11; 56). In a large study of patients with Becker muscular dystrophy, the mean age of onset of muscle symptoms was 11.2 years (range 10 months to 38 years) (11). There appears to be a gradual decline in lower extremity muscle function with age, which typically leads to loss of ambulation, similar to Duchenne muscular dystrophy. However, the age at which loss of ambulation occurs is highly variable, usually after 16 years of age, with a mean age in the third decade (11; 16; 60).

(2) Elevated serum CK. Presymptomatic elevation of serum creatine kinase is a frequent presentation of Becker muscular dystrophy. Striking elevation of serum creatine kinase is present from birth (typically 100 to 200 times normal; normal is less than 200 IU/L) and peaks in the teenage years (mean of 5202 IU/L) (93; 11). It is unusual for serum creatine kinase levels to be below 1000 IU/L in patients with Becker muscular dystrophy. In young patients (less than 3 years old), there is evidence that serum CK levels are inversely proportional to Becker muscular dystrophy disease severity, possibly due to increased energy metabolism within muscle that is proportional to creatine degradation (86). Along with elevated creatine kinase, transaminases (ALT and AST) are also elevated, which may mislead physicians to look for liver diseases.

(3) CNS complications. Central nervous system disorders as an initial symptom of Duchenne muscular dystrophy represent potentially 5.3% of patients. These may include mental retardation, learning disability, epilepsy, or other psychiatric mood disorders. Patients with intellectual/developmental disabilities and seizures more frequently had in-frame deletions in the middle or second half (exon 45 to 55 range) (60).

(4) Cardiac complications. Sixty percent to 75% of patients with Becker muscular dystrophy have at least subclinical cardiac pathophysiology (23; 72). More than 30% of patients in a 2023 natural history study had abnormal electrocardiograms, and 15% suffered from hypertrophic or dilated cardiomyopathy (60). Patients with Becker muscular dystrophy can have dilated cardiomyopathy with or without symptomatic skeletal muscle involvement (19; 43; 76; 85). Sudden cardiac arrest has been reported in patients with Becker muscular dystrophy with undiagnosed disease who undergo anesthesia and surgical procedures (70).

(5) Clinical course. Progression of extremity weakness is variable, and it has been challenging to characterize clinical course with specific genetic mutations or objective measures. All patients with Becker muscular dystrophy show a downward trend on quantitative assessment; however, the majority of clinical progression is most measurable in adulthood (62; 07; 16; 60; 15). Earlier loss of ambulation does appear to be associated with earlier first signs and symptoms (14). Half of affected boys will have muscle weakness by age 10, and the average age of wheelchair introduction/loss of ambulation is in the third decade (11; 60). There are cases of Becker muscular dystrophy with onset of muscle weakness later in life or asymptomatic elevated CK (53; 89). About 10% of patients have severe Becker muscular dystrophy and show delayed motor milestones similar to Duchenne muscular dystrophy; they are wheelchair-bound before 20 years of age, though typically later than patients with Duchenne muscular dystrophy (32). These patients are often called "severe Becker dystrophy," "mild Duchenne dystrophy," or "outliers." There are also rare presentations of Becker muscular dystrophy with calf hypertrophy and elevated CK but without muscle weakness or muscle weakness much later in life (81; 30; 66). In recent natural history studies, more severe clinical involvement is suggested in patients with 45 to X and 45 to 49 deletions (60; 73).

Cardiomyopathy represents the most common cause of death in patients with Becker muscular dystrophy (18; 72). It is unclear whether cardiomyopathy correlates with a distinct phenotype or mutation (38; 40; 44; 16). Cardiomyopathy in Becker muscular dystrophy is thought to be the result of diffuse degeneration and fibrosis in the ventricles, with a preference for the inferolateral region and the conduction tissue (72). Early cardiac screening is necessary for patients with Becker muscular dystrophy. Depending on the age of the patient this includes echocardiography or cardiac magnetic resonance imaging, which is more sensitive (90; 94).

Central nervous system involvement and other nonmuscle symptoms are seen less frequently in Becker muscular dystrophy than in Duchenne muscular dystrophy, but patients with Becker muscular dystrophy do demonstrate a higher incidence of anxiety, learning difficulties, autism, and behavioral problems compared to the general population (91; 58; 49). Additionally, patients who are diagnosed with Becker muscular dystrophy in childhood, independent of clinical progression, more frequently present with a developmental delay and reduced IQ (11b). One study identified the following prevalences: 6.0% of autistic spectrum disorders, 28.0% of attention deficit hyperactivity disorder, 7.0% of depression, 25.0% of anxiety disorders, and 7.0% of obsessive-compulsive disorder (68). Developmental delay and behavioral difficulties have specifically been identified in patients with deletions in exons 45 to 59 (11). In the most recent natural history study, patients with a seizures and intellectual/developmental disabilities more commonly had in-frame deletions in the middle or second half (exon 45 to 55) range (60).

Prognosis and complications

Becker muscular dystrophy is clinically extremely variable. Even with molecular tests it is difficult to determine clinical progression. Patients with more severe Becker muscular dystrophy are typically wheelchair bound between age 14 and 20 years (65; 06; 11b; 17). Overall, patients with Becker muscular dystrophy have a wide range of death, 23 to 89 years, with a mean of 47.3 years, due mainly to respiratory and cardiac disease (11).

Progressive deterioration of muscle can result in contractures and respiratory infections due to reduced vital capacity, particularly in more severely affected patients. Any period of immobility may lead to earlier loss of ambulation (11). Cardiomyopathy and death due to cardiac dysfunction are particular concerns in all patients and may be presenting symptoms in less affected patients, who are able to perform strenuous muscle exercise leading to mechanical stress on dystrophin-deficient myocardial cells (52; 78; 63). Heart function should be carefully monitored in all patients with Becker dystrophy with initiation of early cardiac therapy. Additionally, all female Duchenne and Becker muscular dystrophy carriers over the age of 16 years should have yearly cardiac monitoring (69; 64; 51).

Clinical vignette

The patient was a 9-year-old male who complained of increasing difficulty in climbing stairs, which, he indicated, had started about 6 months prior to the evaluation. He was reported to have had “growing pains” since early childhood, but more recently he had had ankle and calf muscle pain after walking longer distances or running. At 2 years of age, he had undergone a liver biopsy after a routine blood test discovered elevated transaminases. The liver biopsy showed a mild “nonspecific hepatitis” for which no treatment was initiated. His developmental milestones were normal, and he was enrolled in regular school classes. His neurologic examination revealed mild weakness in deltoid muscles, pectoral muscles, and hip flexors, and some of his muscles appeared hypertrophic. He had a partial Gowers sign and tight heel cords bilaterally. His creatine kinase level was 13,500. An echocardiogram did not show any abnormality. A genetic analysis of Duchenne muscular dystrophy gene showed an in-frame deletion of exons 46 and 47.

Biological basis

Etiology and pathogenesis

	• Becker muscular dystrophy is caused by in-frame mutations in the Duchenne muscular dystrophy gene (DMD gene), located on the X-chromosome (Xp21) (48).
	• In Becker muscular dystrophy, dystrophin is present but altered in quantity, quality, or both. This is mainly due to mutations that keep the “reading frame” intact.

Genetics. Becker muscular dystrophy is caused by in-frame mutations in the Duchenne muscular dystrophy gene (DMD gene), located on the X-chromosome (Xp21) (48). The DMD gene occupies 2.5 million base pairs of DNA and is about 10 times larger than the next largest gene identified to date. The gene contains 79 exons of coding sequence, which together form the 14,000 base pair mRNA molecule (48; 74). Several mRNA and protein isoforms vary in size and tissue distribution (02).

Pathophysiology. Dystrophin is localized to the plasma membrane of all myogenic cells (including cardiac muscle) and some classes of neurons and in small amounts in other cell types (36; 39). Isoforms expressed in liver or other nonexcitable tissues do not seem to cause pathology when lacking in patients (02).

Absent dystrophin stain

Absent dystrophin staining (Rod domain) in heart muscle from a patient with Becker muscular dystrophy and cardiomyopathy. (Contributed by Dr. Gyula Acsadi.)

In Becker muscular dystrophy, dystrophin is present but altered in quantity, quality, or both (34; 35). This is mainly due to mutations that keep the “reading frame” intact. In the more severe Duchenne muscular dystrophy, dystrophin is absent due to “out of frame” mutations. Dystrophin deficiency at the plasma membrane of muscle fibers disrupts the membrane cytoskeleton and leads to secondary loss of other components of the cytoskeleton, leading to membrane instability and transient abnormal membrane flux (21). The membrane leakage occurs from birth and causes the classic active myopathy seen histopathologically, yet muscle function is preserved in early childhood. The chronic myopathy leads to aggressive fibrotic replacement of the muscle and eventual failure of regeneration. The clinical severity in Becker muscular dystrophy appears to be linked to structure of truncated dystrophin protein (01; 62).

Advancement in genetic technologies and the expansion of mutation analysis to the introns have increased the list of disease-causing mutations, including, for example, the “founder” mutation in exon 1 (p.Trp3X) that appears to cause a milder Becker phenotype (25; 26).

Differential diagnosis

Confusing conditions

Duchenne muscular dystrophy. The most common presenting symptom of Becker muscular dystrophy, proximal muscle weakness accompanied by striking elevations of serum creatine kinase, is also seen in children diagnosed with Duchenne muscular dystrophy. The age of presentation in Becker muscular dystrophy is typically later than in Duchenne muscular dystrophy and with slower progression, although there can be substantial overlap in more severely affected patients, pointing to the importance of mutational analysis for accurate diagnosis.

Limb girdle muscular dystrophy. It is nearly impossible to differentiate Becker muscular dystrophy from "limb-girdle muscular dystrophy" (autosomal recessive or dominant conditions with multiple etiologies) on clinical grounds (37; 04; 17). Patients with limb-girdle muscular dystrophy generally show lower serum creatine kinase levels and less frequent cardiac involvement compared to patients with Becker muscular dystrophy (37), but there is substantial overlap. Family history can be helpful: an X-linked family history (the affected proband will have maternal uncles or cousins affected) is consistent with Becker muscular dystrophy, whereas affected female siblings strongly suggest autosomal recessive inheritance (limb-girdle muscular dystrophy). Most limb-girdle patients and about 50% of Becker dystrophy patients are isolated cases, and family history is not informative.

Spinal muscular atrophy. A number of patients carrying the diagnosis of late-onset spinal muscular atrophy (Kugelberg-Welander; spinal muscular atrophy types II and III) have been later found to have Becker dystrophy based on molecular tests. Electromyography (EMG) and serum creatine kinase level are usually sufficient in differentiating these patients. Serum CK is only mildly elevated or normal in spinal muscular atrophy. Patients with spinal muscular atrophy show a neurogenic EMG, whereas patients with Becker muscular dystrophy show a myopathic EMG. However, there may be overlap in the EMG patterns and histopathology in advanced cases (ie, end-stage muscular dystrophy with secondary alteration of motor units), and molecular diagnosis is often necessary.

Collagen defects. Collagen defects (Ullrich and Bethlem syndrome) may cause progressive myopathies with proximal weakness, but the presence of hyperlaxed joints represents a distinctive feature (45).

Polymyositis. Patients with polymyositis often show creatine kinase elevations and distribution of weakness that closely resemble Becker muscular dystrophy. However, polymyositis is often more acute in presentation/progression, and all cases are sporadic with no previous family history. Evidence of inflammatory reaction in muscle biopsy is often diagnostic of polymyositis; however, Becker patients can also occasionally show inflammatory infiltrates in muscle. Molecular diagnosis is the most reliable way to differentiate these disorders.

Transient hyperCKemia. HyperCKemia is a frequent presentation of Becker muscular dystrophy. In normal individuals, serum creatine kinase can show elevations following unusual muscle activity (exercise), viral infection, and muscle damage of any kind. However, the degree of elevation in Becker muscular dystrophy is typically greater than 1000 IU/L (normal less than 200 IU/L) and is persistent. In contrast, hyperCKemia due to most other causes in normal individuals is transient, with values usually returning to normal within days or weeks. Serum aldolase and transaminases (alanine transaminase, serine glutamyltransferase) often show less dramatic elevations.

Diagnostic workup

	• Serum creatine kinase levels in patients with Becker muscular dystrophy are always elevated, sometimes up to 200 times normal (normal is less than 200 IU/L).
	• DNA testing should be done for diagnostic confirmation in all patients.
	• The majority of patients with Becker muscular dystrophy have deletion mutations of the DMD gene. Given the high incidence of deletions, it is typically more cost-effective to order DMD gene deletion testing first.
	• Molecular diagnostic tests, including “next-generation sequencing” and other methods, can directly detect nearly all mutations in the dystrophin gene and should be considered if initial deletion testing is negative.
	• Evidence of progressive muscular dystrophy in the mother's brothers or maternal cousins strongly suggests X-linked recessive inheritance. In such cases, prognosis can usually be based on the disease progression in the older male relatives.

Although the diagnosis may be clear from family history, DNA testing should be done on all patients for diagnostic confirmation, potential future genetic treatments, and family counseling; early identification of female carriers with consideration of prenatal diagnosis should be offered to the family (10).

Many patients have no previous family history. The percentage of patients presenting as isolated cases of Becker dystrophy is increasing with the increased use of genetic counseling and molecular diagnosis. Prognosis is more difficult in these cases and must rely on molecular tests. The majority of patients with Becker muscular dystrophy have deletion mutations of the DMD gene; about 80% of patients with Becker muscular dystrophy have deletions, even higher (92.6%) in more typical Becker muscular dystrophy phenotypes (12). Given the high incidence of deletions, it is typically more cost-effective to order DMD gene deletion testing first. There is significant clinical heterogeneity based on the deletion identified. Deletions of exons 45 to 57 seem to be associated solely with milder phenotypes and these patients tend to ambulate into their forties (12). Multiple exon (45-55) deletions have been described in a family with asymptomatic males between the ages of 5 and 69 years (22). A tendency toward earlier wheelchair dependence has been observed with distal exon deletions (83). Various deletions may also be associated with cardiomyopathy or lack of cardiomyopathy (31).

It is important to stress that not all patients with Becker muscular dystrophy have deletion mutations; many have smaller types of mutations including duplications and point mutations that cannot be detected by gene deletion testing. Molecular diagnostic tests including “next-generation sequencing” and other methods can directly detect nearly all mutations in the dystrophin gene and should be considered if initial deletion testing is negative. Depending on costs, these tests could also be considered for initial testing (88; 24; 50; 83).

In patients with high suspicion for Becker muscular dystrophy who test negative for a DMD gene mutation, it is important to test the status of the dystrophin protein in a muscle biopsy (42). This is rarely done in patients with a confirmed genetic diagnosis. Dystrophin levels less than 3% of normal or absent are generally considered diagnostic of Duchenne muscular dystrophy (35). Levels of 12% to 18% usually indicate a milder phenotype such as Becker muscular dystrophy (35).

Abnormal C-terminus dystrophin stain

Abnormal C-terminus dystrophin staining in heart muscle from a patient with Becker Muscular dystrophy and cardiomyopathy. (Contributed by Dr. Gyula Acsadi.)
Absent dystrophin stain

Absent dystrophin staining (Rod domain) in heart muscle from a patient with Becker muscular dystrophy and cardiomyopathy. (Contributed by Dr. Gyula Acsadi.)

Management

	• Management of Becker muscular dystrophy is mostly symptomatic.
	• Patients with Becker muscular dystrophy who show a clinical picture more similar to Duchenne muscular dystrophy, but with later onset and slower progression, may benefit from corticosteroids. Corticosteroids in mild patients are controversial due to side effects.
	• Cardiac monitoring should be done in all patients with Becker muscular dystrophy to evaluate for occult cardiomyopathy.

Glucocorticoid treatment. Mildly affected patients require little intervention, and the slowly progressive weakness may not alter their lifestyle. Corticosteroids in these mild patients are controversial due to side effects. Patients with Becker muscular dystrophy who show a clinical picture more similar to Duchenne muscular dystrophy, but with later onset and slower progression, may benefit from corticosteroids (03). Vamorolone, a dissociative steroid approved for use in Duchenne muscular dystrophy, is currently being studied in Becker muscular dystrophy patients (NCT05166109).

Bone health. More severely affected patients may also benefit from management of contractures or bracing, however, there is no clear evidence that modalities directed at maintaining ankle mobility have any long-term benefit (75).

Pulmonary management. Adult patients with Becker muscular dystrophy experience a significant but mild respiratory decline, which is more rapid and clinically relevant following the loss of ambulation (20). Proactive respiratory care has an important role in the management of patients in the advanced disease stage. Nocturnal respiratory assistance (Bi-PAP) and the use of cough-assisting devices improve survival and the quality of life (80).

Cardiac management. Cardiac monitoring should be done in all patients with Becker muscular dystrophy to include a screening electrocardiogram and echocardiogram at diagnosis and then at least every 2 years and a complete cardiac evaluation starting at 10 years with consideration of cardiac magnetic resonance imaging to evaluate for occult cardiomyopathy (08; 41). Cardiac magnetic resonance imaging is more sensitive in detecting early tissue fibrosis and should be used in place of an echocardiogram if available (31). Additionally, beta-blockers or angiotensin-converting enzyme inhibitors have been shown to prevent progression of myocardial fibrosis with normal ejection fraction (79).

Emerging treatments. Some evolving therapies (eg, gene therapy) in clinical trial being developed for Duchenne muscular dystrophy could be applied to Becker muscular dystrophy (92).

Exon-skipping, which aims to transform the Duchenne muscular dystrophy phenotype into the milder Becker phenotype by restoring the DMD gene reading frame, has less of a role in mild Becker muscular dystrophy (27).

Special considerations

Pregnancy

Becker muscular dystrophy predominantly affects males. Most affected men are able to reproduce, and fertility is not affected. All daughters fathered by a Becker muscular dystrophy patient will be carriers. A Becker muscular dystrophy father does not transmit his dystrophin gene to his sons; thus, all sons will be unaffected.

In female carriers, either manifesting Becker muscular dystrophy or not, there is no reported increased risk during pregnancy, either to the mother or to the child.

Anesthesia

Patients are at increased risk of developing malignant hyperthermia on exposure to halothane anesthetics; thus, these should be avoided (09). In severe cardiomyopathy, a left ventricular device may be used for assisting non-cardiac surgery (87). Anesthesia by isoflurane has been reported to cause rhabdomyolysis and cardiac arrest (70).

COVID-19

Consensus guidelines for the care of patients with Duchenne muscular dystrophy during the COVID-19 pandemic have been published. Recommendations include continuing current corticosteroid regiments with potential dose adjustments should they become ill to prevent adrenal insufficiency and consideration of stress dose steroids in the setting of acute illness or hospitalization. Exon-skipping agents are encouraged to be continued. The risks and benefits of receiving these infusions during a pandemic should be discussed with the patient’s neurologist. It is recommended that angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prophylaxis or treatment of cardiomyopathy should be continued. Those with chronic respiratory insufficiency should be treated in collaboration with pulmonary or anesthesiology specialists and should not receive supplemental oxygen without ventilatory support. Finally, hydroxychloroquine has uncertain benefit and may cause skeletal or cardiac muscle damage (84). Thus, it should not be prescribed for this patient population.

In a small study of children with neuromuscular conditions and documented SARS-CoV-2 infection (n=29, five Duchenne muscular dystrophy/Becker muscular dystrophy subjects), 89% of patients were asymptomatic or had mild symptoms, including mild upper respiratory symptoms and fever (61). Ten percent of patients had moderate symptoms, including mild respiratory distress without respiratory decline. In a separate review of seven adults with Duchenne muscular dystrophy and SARS-CoV-2, no patients developed moderate to severe symptoms, and all patients with mild symptoms recovered without complication or hospitalization (71). These results indicate that young age may have a protective role, which outweighs neuromuscular risk factors, including reduced respiratory capacity. These findings may also indicate that the known SARS-CoV-2 variants may not be more life-threatening than other respiratory viruses in this population.

References

01: Acsadi G, Moore SA, Chéron A, et al. Novel mutation in spectrin-like repeat 1 of dystrophin central domain causes protein misfolding and mild Becker muscular dystrophy. J Biol Chem 2012;287(22):18153-62. PMID 22453924
02: Ahn AH, Kunkel LM. The structural and functional diversity of dystrophin. Nat Genet 1993;3:283-91. PMID 7981747
03: Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve 2007;36(4):424-35. PMID 17541998
04: Arikawa E, Hoffman EP, Kaido M, Nonaka I, Sugita H, Arahata K. The frequency of patients having dystrophin abnormalities in a limb-girdle patient population. Neurology 1991;41:1491-6. PMID 1842672
05: Becker PE, Kiener F. Eine neue X-chromosomale muskeldystrophie. Arch Psychiatr Z Neurol 1955;193:427.
06: Beggs AH, Hoffman EP, Snyder JR, et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 1991;49:54-67. PMID 2063877
07: Bello L, Paola C, Barp A, et al. Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathies. Sci Rep 2016;6:32439. PMID 27582364
08: Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 2018;17(4):347-61. PMID 29395990
09: Bush A, Dubowitz V. Fatal rhabdomyolysis complicating general anaesthesia in a child with Becker muscular dystrophy. Neuromuscul Disord 1991;1:201-4. PMID 1822795
10: Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9(1):77-93. PMID 19945913
11: Bushby KM, Gardner-Medwin D, Nicholson LV, et al. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. J Neurol 1993a;240:98-112.** PMID 8437017
12: Bushby KM, Gardner-Medwin D, Nicholson LV, et al. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities. J Neurol 1993b;240:105-12.** PMID 8437017
13: Bushby KM, Thambyayah M, Gardner-Medwin D. Prevalence and incidence of Becker muscular dystrophy. Lancet 1991;337:1022-4. PMID 1673177
14: Ciafaloni E, Kumar A, Liu K, et al. Age at onset of first signs of symptoms predicts age at loss of ambulation in Duchenne and Becker muscular dystrophy: data from the MD STARnet. J Pediatr Rehabilitations Med 2016;9(1):5-11. PMID 26966795
15: Clemens PR, Gordish-Dressman H, Niizzawa G, et al. Findings from the longitudinal CINRG Becker Natural History Study. J Neuromuscul Dis 2024;11(1):201-12. PMID 37980682
16: Clemens PR, Niizawa G, Feng J, et al. The CINRG Becker Natural History Study: baseline characteristics. Muscle Nerve 2020;62(3):369-76. PMID 32564389
17: Comi GP, Prelle A, Bresolin N, et al. Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. Brain 1994;117:1-14. PMID 8149204
18: Connuck DM, Sleeper LA, Colan SD, et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 2008;155:998-1005. PMID 18513510
19: Davies JE, Winokur TS, Aaron MF, Benza RL, Foley BA, Holman WL. Cardiomyopathy in a carrier of Duchenne's muscular dystrophy. J Heart Lung Transplant 2001;20(7):781-4. PMID 11448811
20: De Wel B, Willaert S, Nadaj-Pakleza A, et al. Respiratory decline in adult patients with Becker muscular dystrophy: a longitudinal study. Neuromuscul Disord 2021;31(3):174-82. PMID 33454189
21: Draviam R, Billington L, Senchak A, Hoffman EP, Watkins SC. Confocal analysis of the dystrophin protein complex in muscular dystrophy. Muscle Nerve 2001;24(2):262-72. PMID 11180210
22: Ferreiro V, Giliberto F, Muñiz GM, et al. Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion. Muscle Nerve 2009;39(2):239-43. PMID 19012301
23: Finsterer J, Stollberger C. Cardiac involvement in Becker muscular dystrophy. Can J Cardiol 2008;24(10):786-92. PMID 18841259
24: Flanigan KM, von Niederhausern A, Dunn DM, Alder J, Mendell JR, Weiss RB. Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet 2003;72(4):931-9. PMID 12632325
25: Flanigan KM, Dunn DM, von Niederhausern A, et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 2009a;30(12):1657-66. PMID 19937601
26: Flanigan KM, Dunn DM, von Niederhausern A, et al. DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy. Neuromuscul Disord 2009b;19(11):743-8. PMID 19793655
27: Fletcher S, Adams AM, Johnsen RD, Greer K, Moulton HM, Wilton SD. Dystrophin isoform induction in vivo by antisense-mediated alternative splicing. Mol Ther 2010;18(6):1218-23. PMID 20332768
28: Gatheridge MA, Kwon JM, Mendell JM, et al. Identifying non-Duchenne muscular dystrophy-positive and false negative results in prior Duchenne muscular dystrophy newborn screening programs: a review. JAMA Neurol 2016;73(1):111-6. PMID 26594870
29: Gospe SM, Lazaro RP, Lava NS, Grootscholten PM, Scott MO, Fischbeck KH. Familial X-linked myalgia and cramps. Neurology 1989;39:1277-80. PMID 2677830
30: Heald A, Anderson LV, Bushby KM, Shaw PJ. Becker muscular dystrophy with onset after 60 years. Neurology 1994;44:2388-90. PMID 7991131
31: Ho R, Nguyen M, Mather P. Cardiomyopathy in becker muscular dystrophy: overview. World J Cardio 2016;8(6):356-61. PMID 27354892
32: Hoffman EP. Genotype/phenotype correlations in Duchenne/Becker dystrophy. Mol Cell Biol Hum Dis Ser 1993;3:12-36. PMID 8111537
33: Hoffman EP, Arahata K, Minetti C, et al. Dystrophinopathy in isolated cases of myopathy in females. Neurology 1992;42:967-75. PMID 1579251
34: Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-28. PMID 3319190
35: Hoffman EP, Fischbeck KH, Brown RH, et al. Dystrophin characterization in muscle biopsies from Duchenne and Becker muscular dystrophy patients. N Engl J Med 1988a;318:1363-8. PMID 3285207
36: Hoffman EP, Hudecki M, Rosenberg P, Pollina C, Kunkel LM. Cell and fiber-type distribution of dystrophin. Neuron 1988b;1:411-20. PMID 3078411
37: Hoffman EP, Kunkel LM, Angelini C, Clarke A, Johnson M, Harris JB. Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology 1989;39:1011-7. PMID 2668783
38: Hoogerwaard EM, de Voogt WG, Wilde AA, et al. Evolution of cardiac abnormalities in Becker muscular dystrophy over a 13-year period. J Neurol 1997;244(10):657-63. PMID 9402544
39: Houzelstein D, Lyons GE, Chamberlain J, Buckingham ME. Localization of dystrophin gene transcripts during mouse embryogenesis. J Cell Biol 1992;119:811-21. PMID 1429837
40: Jefferies FL, Eidem BW, Belmont JW, et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005;112(18):2799-804. PMID 16246949
41: Johnston TP, Cripe LH, Mah ML, et al. Young Becker muscular dystrophy patients demonstrate fibrosis associated with abnormal left ventricular ejection fraction on cardiac magnetic resonance imaging. Circ Cardiovasc Imaging 2019;12(7):e008919. PMID 31487197
42: Jones HF, Bryen SJ, Waddell LB, et al. Importance of muscle biopsy to establish pathogenicity of DMD missense and splice variants. Neuromuscul Disord 2019;29(12):913-9. PMID 31706698
43: Kaminaga T, Matsumura K, Hatanaka H, Shimizu T. Abnormality of the myocardial sympathetic nervous system in a patient with Becker muscular dystrophy detected with iodine-123 metaiodobenzylguanidine scintigraphy. Clin Nucl Med 2001;26(8):701-3 PMID 11452178
44: Kaspar RW, Allen HD, Ray WC, et al. Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy. Circ Cardiovasc Genet 2009;2(6):544-51. PMID 20031633
45: Kawahara G, Okada M, Morone N, et al. Reduced cell anchorage may cause sarcolemma-specific collagen VI deficiency in Ullrich disease. Neurology 2007;69(10):1043-9. PMID 17785674
46: Ke Q, Zhao ZY, Griggs R, et al. Newborn screening for Duchenne muscular dystrophy in China: follow-up diagnosis and subsequent treatment. World J Pediatr 2017;13(3):197-201. PMID 28466241
47: Ke Q, Zhao ZY, Mendell JR, et al. Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy. World J Pediatr 2019;15(3):219-22. PMID 30904991
48: Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50:509-17. PMID 3607877
49: Lambert JT, Darmahkasih AJ, Horn PS, et al. Neurodevelopmental, behavioral, and emotional symptoms in Becker muscular dystrophy. Muscle Nerve 2020;61(2):156-62. PMID 31650559
50: Lim BC, Lee S, Shin JY, et al. Genetic diagnosis of Duchenne and Becker muscular dystrophy using next-generation sequencing technology: comprehensive mutational search in a single platform. J Med Genet 2011;48(11):731-6. PMID 21969337
51: Mavrogeni S, Markousis-Mavrogenis G, Papavasiliou A, Kolovou G. Cardiac involvement in Duchenne and Becker muscular dystrophy. World J Cardiol 2015;7(7):410-4. PMID 26225202
52: Melacini P, Fanin M, Danieli GA, et al. Cardiac involvement in Becker muscular dystrophy. J Am Coll Cardiol 1993;22:1927-34. PMID 8245351
53: Melis MA, Cau M, Muntoni F, et al. Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families. Eur J Paediatr Neurol 1998;2(5):255-61. PMID 10726828
54: Mendell JR, Shilling C, Leslie ND, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 2012;71(3):304-13. PMID 22451200
55: Minetti C, Chang HW, Medori R, et al. Dystrophin deficiency in young girls with sporadic myopathy and normal karyotype. Neurology 1991;41:1288-91. PMID 1714059
56: Minetti C, Tanji K, Chang HW, et al. Dystrophinopathy in two young boys with exercise-induced cramps and myoglobinuria. Eur J Pediatr 1993;152:848-51. PMID 8223790
57: Monaco AP, Neve RL, Colletti-Feener C, Bertelson CJ, Kurnit DM, Kunkel LM. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 1986;323:646-50. PMID 3773991
58: Mori-Yoshimura M, Mizuno Y, Yoshida S, et al. Psychiatric and neurodevelopmental aspects of Becker muscular dystrophy. Neuromuscul Disord 2019;29(12):930-9. PMID 31708335
59: Moser H. Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention. Hum Genet 1984;66(1):17-40. PMID 6365739
60: Nakamura A, Matsumura T, Ogata K, et al. Natural history of Becker muscular dystrophy: a multicenter study of 225 patients. Ann Clin Transl Neurol 2023;10(12):2360-72. PMID 37882106
61: Natera-de Benito D, Aguilera-Albesa S, Costa-Comellas L, et al. Covid-19 in children with neuromuscular disorders. J Neurol 2021;268(9):3081-5. PMID 33387010
62: Nicolas A, Raguénès-Nicol C, Ben Yaou R, et al. Becker muscular dystrophy severity is linked to the structure of dystrophin. Hum Mol Genet 2015;24(5):1267-79. PMID 25348330
63: Nigro G, Comi LI, Politano L, et al. Evaluation of the cardiomyopathy in Becker muscular dystrophy. Muscle Nerve 1995;18:283-91. PMID 7870105
64: Nolan MA, Jones OD, Pedersen RL, Johnston HM. Cardiac assessment in childhood carriers of Duchenne and Becker muscular dystrophies. Neuromuscul Disord 2003;13(2):129-32. PMID 12565910
65: Norman AM, Thomas NS, Kingston HM, Harper PS. Becker muscular dystrophy: correlation of deletion type with clinical severity. J Med Genet 1990;27:236-9. PMID 2325103
66: Palmucci L, Doriguzzi C, Mongini T, Restagno G, Chiado-Piat L, Maniscalco M. Unusual expression and very mild course of Xp21 muscular dystrophy (Becker type) in a 60-year-old man with 26 percent deletion of the dystrophin gene. Neurology 1994;44:541-3. PMID 8145928
67: Papa R, Madia F, Bartolomeo D, et al. Genetic and early clinical manifestations of females heterozygous for Duchenne/Becker muscular dystrophy. Pediatr Neurol 2016;55:58-63. PMID 26718981
68: Pascual-Morena C, Cavero-Redondo I, Reina-Gutierrez S, et al. Prevalence of neuropsychiatric disorders in Duchenne and Becker muscular dystrophies: a systematic review and meta-analysis. Arch Phys Med Rehabil 2022;103(12):2444-53. PMID 35839922
69: Politano L, Nigro V, Nigro G, et al. Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. JAMA 1996;275(17):1335-8. PMID 8614119
70: Poole TC, Lim TY, Buck J, Kong AS. Perioperative cardiac arrest in a patient with previously undiagnosed Becker's muscular dystrophy after isoflurane anaesthesia for elective surgery. Br J Anaesth 2010;104(4):487-9. PMID 20190256
71: Quinlivan R, Mahalekshmi D, Cruces F, Pietrusz A, Savvatis K. Clinical outcome of SARS-CoV-2 infection in 7 adults with Duchenne muscular dystrophy attending a specialist neuromuscular centre. Neuromuscul Disord 2021;31(7):603-6. PMID 34049776
72: Rajdev A, Groh WJ. Arrhythmias in the muscular dystrophies. Card Electrophysiol Clin 2015;7(2):303-8. PMID 26002394
73: Ricci G, Govoni A, Torri F, et al. Characterization of phenotypic variability in Becker muscular dystrophy for clinical practice and towards trial readiness: A two years follow up study. Neuromuscular Dis 2024;11(2):375-87. PMID 38189759
74: Roberts RG, Coffey AJ, Bobrow M, Bentley DR. Exon structure of the human dystrophin gene. Genomics 1993;16:536-8. PMID 8314593
75: Rose KJ, Burns J, Wheeler DM, North KN. Interventions for increasing ankle range of motion in patients with neuromuscular disease. Cochrane Database Syst Rev 2010;2:CD006973. PMID 20166090
76: Saotome M, Yoshitomi Y, Kojima S, Kuramochi M. Dilated cardiomyopathy of Becker-type muscular dystrophy with exon 4 deletion: a case report. Angiology 2001;52(5):343-7. PMID 11386386
77: Scully MA, Farrell PM, Ciafaloni E, Griggs RC, Kwon JM. Cystic fibrosis newborn screening: a model for neuromuscular disease screening? Ann Neurol 2015;77(2):189-97. PMID 25425541
78: Siciliano G, Fanin M, Angelini C, et al. Prevalent cardiac involvement in dystrophin Becker type mutation. Neuromuscul Disord 1994;4:381-6. PMID 7981595
79: Silva MC, Magalhaes TA, Meira ZM, et al. Myocardial fibrosis progression in Duchenne and Becker muscular dystrophy: a randomized clinical trial. JAMA Cardiol 2017;2(2):190-9. PMID 27926769
80: Simonds AK. Recent advances in respiratory care for neuromuscular disease. Chest 2006;130(6):1879-86. PMID 17167012
81: Tachi N, Wakai S, Watanabe Y, Ohya K, Chiba S. Asymptomatic Becker muscular dystrophy: expression of dystrophin and dystrophin-related protein. Pediatr Neurol 1993;9:207-9. PMID 8352853
82: Tavakoli NP, Gruber D, Armstrong K et al. Newborn screening for Duchenne muscular dystrophy: a two-year pilot study. Ann Clin Trans Neurol 2023;10(8):1383-96. PMID 37350320
83: Vengalil S, Preethish-Kumar V, Polavarapu K. Duchenne muscular dystrophy and Becker muscular dystrophy confirmed by multiplex ligation-dependent probe amplification: genotype-phenotype correlation in a large cohort. J Clin Neurol 2017;13(1):91-7. PMID 28079318
84: Veerapandiyan A, Wagner KR, Apkon S, et al. The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID-19 pandemic. Muscle Nerve 2020;62(1):41-5. PMID 32329920
85: Vita G, Di Leo R, De Gregorio C, et al. Cardiovascular autonomic control in Becker muscular dystrophy. J Neurol Sci 2001;186(1-2):45-9. PMID 11412871
86: Wang L, Chen M, He R, et al. Serum creatinine distinguishes Duchenne muscular dystrophy from Becker muscular dystrophy in patients aged ≤3 years: a retrospective study. Front Neurol 2017;8:196. PMID 28533764
87: Webb ST, Patil V, Vuylsteke A. Anaesthesia for non-cardiac surgery in patient with Becker's muscular dystrophy supported with a left ventricular assist device. Eur J Anaesthesiol 2007;24(7):640-2. PMID 17632873
88: White S, Kalf M, Liu Q, et al. Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization. Am J Hum Genet 2002;71(2):365-74. PMID 12111668
89: Yazaki M, Yoshida K, Nakamura A, et al. Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. Eur Neurol 1999;42(3):145-9. PMID 10529540
90: Yilmaz A, Gdynia HJ, Baccouche H, et al. Cardiac involvement in patients with Becker muscular dystrophy: new diagnostic and pathophysiological insights by a CMR approach. J Cardiovasc Magn Reson 2008;10(1):50. PMID 18983659
91: Young HK, Barton BA, Waisbren S, et al. Cognitive and psychological profile of males with Becker muscular dystrophy. J Child Neurol 2008;23(2):155-62. PMID 18056690
92: Zaidman CM, Proud CM, McDonald CM, et al. Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR). Ann Neurol 2023;94(5):955-68. PMID 37539981
93: Zatz M, Rapaport D, Vainzof M, et al. Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy. J Neurol Sci 1991;102(2):190-6. PMID 2072118
94: Zhang L, Liu Z, Hu KY, et al. Early myocardial damage assessment in dystrophinopathies using 99Tcm-MIBI gated myocardial perfusion imaging. Ther Clin Risk Manag 2015;11:1819-27. PMID 26677332

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Michele Gatheridge MD

Dr. Gatheridge of the University of Rochester Medical Center has no relevant financial relationships to disclose.
See Profile

Editor

Nicholas E Johnson MD MSCI FAAN

Dr. Johnson of Virginia Commonwealth University received consulting fees and/or research grants from AMO Pharma, Avidity, Dyne, Novartis, Pepgen, Sanofi Genzyme, Sarepta Therapeutics, Takeda, and Vertex, consulting fees and stock options from Juvena, and honorariums from Biogen Idec and Fulcrum Therapeutics as a drug safety monitoring board member.
See Profile

Former Authors

Eric Hoffman PhD
Elena Pegoraro MD
Gyula Acsadi MD PhD
Emma Ciafaloni MD FAAN
Michael K Hehir MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: male>female, >2:1
Heredity: heredity may be a factor

sex-linked recessive
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Hereditary progressive muscular dystrophy: 359.1
ICD-10: Muscular dystrophy: G71.0
OMIM: Muscular dystrophy, Becker type: #300376

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Becker muscular dystrophy

Associated Disorders

Duchenne muscular dystrophy
Dystrophinopathy|
Myoglobinuria
Proximal limb-girdle weakness

Differential Diagnosis

limb-girdle muscular dystrophy
polymyositis
chronic forms of spinal muscular atrophy (Kugelberg-Welander, spinal muscular atrophy types 2 and 3)
congenital muscular dystrophy
Kugelberg-Welander disease
- metabolic myopathies
- proximal weakness
- hyper-CKemia

Also Relevant

Duchenne muscular dystrophy
Gene therapy of muscular dystrophy
Limb-girdle muscular dystrophies
Management of chronic neuromuscular disease in children
Molecular diagnosis of neurogenetic disorders
- Neuromuscular pathology: overview

Clinical Categories

Neuromuscular Disorders

Patient Handouts

Muscular dystrophy

Web References

Guidelines

AAN: Neuromuscular guidelines

	• Becker muscular dystrophy affects approximately 1 in 18,450 live male births compared to 1 in 5000 males affected with Duchenne muscular dystrophy (13; 54).
	• Ten percent of isolated cases of “idiopathic hyper-CKemic myopathy” in females are isolated cases of dystrophinopathy carriers.

	• Becker muscular dystrophy is transmitted to male offspring by female carriers, as is typical of X-linked recessive conditions. The clinical course cannot be prevented.
	• Families with Becker muscular dystrophy are counseled similarly to families with Duchenne muscular dystrophy, except that Becker patients are more likely to reproduce than Duchenne patients.

Becker muscular dystrophy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

COVID-19

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Neurogenetics and genetic and genomic testing

Asymptomatic hyperCKemia

Limb-girdle muscular dystrophies

Chronic progressive external ophthalmoplegia

Drug-induced myasthenic syndromes

Distal myopathies

Amyotrophic lateral sclerosis

ALS-like disorders of the Western Pacific

This is an article preview.
Start a Free Account
to access the full version.